Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Share-based Compensation (2017 - 2025)

Arcus Biosciences has reported Share-based Compensation over the past 9 years, most recently at $15.0 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $15.0 million for Q4 2025, down 11.76% from a year ago — trailing twelve months through Dec 2025 was $60.0 million (down 21.05% YoY), and the annual figure for FY2025 was $60.0 million, down 21.05%.
  • Share-based Compensation for Q4 2025 was $15.0 million at Arcus Biosciences, up from $14.0 million in the prior quarter.
  • Over the last five years, Share-based Compensation for RCUS hit a ceiling of $20.0 million in Q1 2024 and a floor of $12.8 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $16.6 million (2022), compared with a mean of $16.5 million.
  • Biggest five-year swings in Share-based Compensation: surged 268.6% in 2021 and later dropped 26.32% in 2025.
  • Arcus Biosciences' Share-based Compensation stood at $14.3 million in 2021, then rose by 18.99% to $17.0 million in 2022, then grew by 5.88% to $18.0 million in 2023, then fell by 5.56% to $17.0 million in 2024, then fell by 11.76% to $15.0 million in 2025.
  • The last three reported values for Share-based Compensation were $15.0 million (Q4 2025), $14.0 million (Q3 2025), and $15.0 million (Q2 2025) per Business Quant data.